Roche Terminates Cancer Treatment Pact With Blueprint Medicines
Roche Holdings AG has decided to terminate its collaboration agreement with Blueprint Medicines Corporation for strategic reasons, allowing Blueprint Medicines to regain global commercialization and development rights to Gavreto (pralsetinib), except in Greater China. The termination will be effective in 12 months. Blueprint Medicines plans to explore options to advance and simplify the continued global commercialization and development of Gavreto, which was approved by the FDA for three indications in lung and thyroid cancer settings. The company anticipates no impact on its 2023 revenue guidance and expects its current cash position and future product revenues to enable it to achieve a self-sustainable financial profile.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
